News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Novocure Reports Second Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ICON plc (NASDAQ: ICLR) ) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company
Chemed Reports Second-Quarter 2022 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Acadia Healthcare Reports Second Quarter 2022 Results and Raises 2022 Guidance
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2022.
Second Quarter Highlights
-
Revenue totaled $651.7 million, an
ICON Reports Second Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2022.
CEO Dr. Steve
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN ergänzt digitales PCR-Portfolio QIAcuity um neue Biopharma-Produkte und führt Expert Custom Assay Design Service ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute mehrere Erweiterungen seiner Instrumente für digitalen PCR (dPCR) der QIAcuity-Serie bekannt. Mit den Neuerungen soll der Einsatz des
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers
QIAGEN übertrifft Ausblick für zweites Quartal und erhöht Prognose für das Gesamtjahr 2022
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das zweite Quartal 2022 bekannt und hob die Prognose für das Gesamtjahr 2022 an.
Der Konzernumsatz sank im
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
Net sales for Q2 2022 declined 9% (-4% at
Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its decision-support software platform QIAGEN Clinical Insights (QCI) has been used to interpret more than three million
QIAGENs Plattform zur Unterstützung von klinischen Entscheidungsfindungen überschreitet Marke von drei Millionen NGS-Patiententests
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass mit QIAGEN Clinical Insights (QCI), der unternehmenseigenen Plattform zur Unterstützung klinischer Entscheidungsfindungen
Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with ECU Health (formerly Vidant Health), eastern North Carolina’s premier health system. The new